Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amicus Therapeutics has got $500,000 as second grant from The Michael J Fox Foundation for Parkinson's Research (MJFF) for the development of a novel, pharmacological chaperone for the treatment of Parkinson's disease.
Subscribe to our email newsletter
The studies will focus on the parkinson’s-implicated protein alpha-synuclein.
Amicus chief scientific officer David Lockhart said that they are honored to receive this grant from the MJFF, which will help us further develop their novel treatment for parkinson’s disease.
"The targeted compounds that we have discovered have shown promising effects in initial animal studies, and we are delighted to be working together with the MJFF and Chesselet to advance our lead compound into advanced preclinical studies," Lockhart said.
Amicus chairman and CEO John Crowley said that they appreciate MJFF’s backing of their pharmacological chaperone technology and believe this grant further demonstrates the strong scientific capabilities at Amicus.